Pfizer Inc. (PFE) — closed signal from February 27, 2026
Partial Published before the outcome was known, scored automatically when the window closed on May 28, 2026.
Predicted vs. what happened
What happened
Reached 43% of the predicted growth at its peak, without hitting the target.
The thesis — published February 27, 2026
Pfizer just got full FDA approval for a cancer drug, which can change how investors feel about the stock over the next few weeks. The company is coming off a long down period and now sits in a quieter price area where buyers can enter without chasing big gains. The main risk is that the initial excitement fades or the drug doesn't drive steady demand.
Primary drivers
- FDA approval for BRAFTOVI can renew investor interest
- Being a large, established drug company helps steady demand
- Current base gives a clearer level to place buys and limits loss
- Future gains need ongoing demand after the approval
How it played out
PFE: target stayed out of reach
Lyra published PFE at $27.13 on 2026-02-27 for a short-term window ending 2026-05-28. The thesis expected 14% growth and pointed to full FDA approval for BRAFTOVI, Pfizer's scale as an established drug company, a quieter price area for entry, and the need for demand after the approval to keep gains going.
Inside the window, PFE rose to a peak of $28.75 on 2026-04-02, a 6% gain. It stayed below the $30.92 target. By 2026-05-28, it ended at $26.14. The thesis partially played out early, but the target was missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.